ArticleBrain communications2022
Unravelling the relationship between amyloid accumulation and brain network function in normal aging and very mild cognitive decline: a longitudinal analysis.
Article in Brain communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Cell-based polygenic risk scores predict clinical progression and prioritize network-based therapeutic targets in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Excitation-inhibition homeostasis in Alzheimer's disease: a selective multiscale review of mechanisms, sex differences, and therapeutic opportunities.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Disrupted Energetic and Entropic Landscape in Individuals With Mild Cognitive Impairment: Insights From Network Control Theory.Human brain mapping · 2025Article
- Longitudinal biomarker studies in human neuroimaging: capturing biological change of Alzheimer's pathology.Alzheimer's research & therapy · 2025Review
- Longitudinal Analysis of Amyloid PET and Brain MRI for Predicting Conversion from Mild Cognitive Impairment to Alzheimer's Disease: Findings from the ADNI Cohort.Tomography (Ann Arbor, Mich.) · 2025Article
- Changes in dementia risk along with onset age of depression: a longitudinal cohort study of elderly depressed patients.BMC psychiatry · 2025Article
- Age differences in BOLD modulation to task difficulty as a function of amyloid burden.Cerebral cortex (New York, N.Y. : 1991) · 2024Article
- Inequalities in the Prevention and Treatment of Alzheimer Disease.Neurology. Clinical practice · 2024Article
- Autism Spectrum Disorder: Brain Areas Involved, Neurobiological Mechanisms, Diagnoses and Therapies.International journal of molecular sciences · 2024Review
- Generative AI unlocks PET insights: brain amyloid dynamics and quantification.Frontiers in aging neuroscience · 2024Article
- Is Alzheimer's disease an individual-centered disease? Hypotheses from the atomic levels up to mathematical models for biological systems.Frontiers in neurology · 2024Article
- Neurophysiological markers of early cognitive decline in older adults: a mini-review of electroencephalography studies for precursors of dementia.Frontiers in aging neuroscience · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pathological changes in the brain begin accumulating decades before the appearance of cognitive symptoms in Alzheimer's disease. The deposition of amyloid beta proteins and other neurotoxic changes occur, leading to disruption in functional connections between brain networks. Discrete characterization of the changes that take place in preclinical Alzheimer's disease has the potential to help treatment development by targeting the neuropathological mechanisms to prevent cognitive decline and dementia from occurring entirely. Previous research has focused on the cross-sectional differences in the brains of patients with mild cognitive impairment or Alzheimer's disease and healthy controls or has concentrated on the stages immediately preceding cognitive symptoms. The present study emphasizes the early preclinical phases of neurodegeneration. We use a longitudinal approach to examine the brain changes that take place during the early stages of cognitive decline in the Open Access Series of Imaging Studies-3 data set. Among 1098 participants, 274 passed the inclusion criteria (i.e. had at least two cognitive assessments and two amyloid scans). Over 90% of participants were healthy at baseline. Over 8-10 years, some participants progressed to very mild cognitive impairment (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.